Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VRAX 
Virax Biolabs Group Limited Ordinary Shares (VRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.38% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.67M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.62 | 52 Weeks Range 0.52 - 3.62 | Updated Date 10/17/2025 |
52 Weeks Range 0.52 - 3.62 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -238316.85% |
Management Effectiveness
Return on Assets (TTM) -64.68% | Return on Equity (TTM) -114.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1200742 | Price to Sales(TTM) 421.85 |
Enterprise Value -1200742 | Price to Sales(TTM) 421.85 | ||
Enterprise Value to Revenue 27.27 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 4341956 | Shares Floating 3676030 |
Shares Outstanding 4341956 | Shares Floating 3676030 | ||
Percent Insiders 10.08 | Percent Institutions 6.06 |
Upturn AI SWOT
Virax Biolabs Group Limited Ordinary Shares
Company Overview
History and Background
Virax Biolabs Group Limited is a biotechnology company focused on the detection, prevention, and diagnosis of viral diseases. Founded with the goal of addressing global health challenges, the company has evolved to offer a range of diagnostic and therapeutic products.
Core Business Areas
- Diagnostic Kits: Development and distribution of diagnostic kits for various viral diseases, including COVID-19, influenza, and others.
- Therapeutic Research: Research and development of therapeutic solutions targeting viral infections.
- Point-of-Care Testing: Offering point-of-care testing solutions for rapid and accurate viral disease detection.
Leadership and Structure
Information on leadership and organizational structure is limited in readily available public sources. Additional internal research would be necessary.
Top Products and Market Share
Key Offerings
- COVID-19 Diagnostic Kits: Virax Biolabs offers a range of COVID-19 diagnostic kits, including PCR and rapid antigen tests. Market share data is difficult to ascertain without proprietary sales figures. Competitors include Abbott, Roche, and QuidelOrtho.
- Influenza Diagnostic Kits: Influenza diagnostic kits for detection of influenza A and B. Market share data is difficult to ascertain without proprietary sales figures. Competitors include Abbott, Roche, and Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The diagnostic and therapeutic industry is characterized by rapid innovation, intense competition, and evolving regulatory landscapes. The COVID-19 pandemic significantly accelerated the growth of the diagnostic market.
Positioning
Virax Biolabs is positioned as a provider of diagnostic and therapeutic solutions with a focus on viral diseases. Its competitive advantage is unknown without proprietary information.
Total Addressable Market (TAM)
The global diagnostics market is estimated to be in the hundreds of billions of dollars. Virax Biolabs' positioning within this TAM is dependent on its product offerings, market penetration, and competitive landscape. Further analysis is needed to determine the company's TAM capture rate.
Upturn SWOT Analysis
Strengths
- Focus on viral disease diagnostics
- Potential for innovation in therapeutic solutions
Weaknesses
- Limited publicly available information
- Smaller scale compared to major competitors
- Reliance on specific product lines
- Unknown financial strength
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic and therapeutic products
- Partnerships and collaborations with other companies
- Increased demand for rapid and accurate diagnostics
- Government funding and support for research and development
Threats
- Intense competition from larger players
- Regulatory changes and approvals
- Technological obsolescence
- Economic downturns
- Supply chain disruptions
- Negative clinical trial results
Competitors and Market Share
Key Competitors
- ABT
- RHHBY
- TMO
Competitive Landscape
Virax Biolabs faces strong competition from well-established players with greater resources and broader product portfolios. Overcoming this requires focused innovation and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Insufficient publicly available data to discuss historical growth trends. Financial information can be sourced directly from the company reports.
Future Projections: Insufficient publicly available analyst estimates. Future growth projections require access to company forecasts and market analysis reports.
Recent Initiatives: Data not available. Recent initiatives require access to company press releases, investor relations reports, and news articles.
Summary
Virax Biolabs Group Limited Ordinary Shares is focused on viral disease diagnostics, but faces significant competition from larger companies. Their success depends on developing innovative products and effective market penetration. Lack of financial data and limited public information hinders a comprehensive assessment, but their focus niche positions them for growth if executed properly.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website (if available)
- SEC filings (if available)
- Market research reports (if available)
- News articles (if available)
- Third Party Financial Websites (if available)
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. This analysis is for informational purposes only and is subject to change based on new information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Virax Biolabs Group Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-07-21 | Chairman, CEO & Principal Accounting Officer Mr. James Foster | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://viraxbiolabs.com |
Full time employees 19 | Website https://viraxbiolabs.com | ||
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.